Laryngeal Histoplasmosis in patients with Crohn’s Disease undergoing treatment with HUMIRA (adalimumab): A Case Series

Authors

Jenna Berg, University of Nebraska Medical CenterFollow
Jonathan Blecha, University of Nebraska Medical CenterFollow
Chris Bingcang, University of Nebraska Medical CenterFollow
Justin Oltman, University of Nebraska Medical CenterFollow
Jayme Dowdall, University of Nebraska Medical CenterFollow
Subodh M. Lele, University of Nebraska Medical CenterFollow

ORCID (Optional)

https://orcid.org/0000-0002-2286-9749

Document Type

Case Report

Disciplines

Digestive System Diseases | Gastroenterology | Higher Education | Medicine and Health Sciences | Otolaryngology

Abstract

The FDA has advocated for increasing awareness of histoplasmosis for patients undergoing TNF blockers as delay in diagnosis can lead to a poor outcome.¹ Laryngeal histoplasmosis is a rare entity that should be part of the differential diagnosis in patients receiving immune suppression for Crohn’s disease. Patients with laryngeal histoplasmosis often report hoarseness, mucosal ulcerations, dysphagia, and odynophagia. We present a series of two cases of laryngeal histoplasmosis in patients with Crohn’s. These cases illustrate the high index of suspicion required to make the diagnosis of laryngeal histoplasmosis, especially in the Midwestern United States. Diagnosis is made quickly and cost-effectively with proper staining. Delayed diagnosis may lead to dissemination, increased morbidity, and mortality.

DOI

10.32873/unmc.dc.gmerj.2.1.009

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Recommended Citation

Berg, J., Blecha, J., Bingcang, C., Oltman, J., Dowdall, J., , Lele, S. M. Laryngeal Histoplasmosis in patients with Crohn’s Disease undergoing treatment with HUMIRA (adalimumab): A Case Series. Graduate Medical Education Research Journal. 2020 Sep 29; 2(1).
https://digitalcommons.unmc.edu/gmerj/vol2/iss1/10